Related Experiment Videos
Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer
U Feine1, R Lietzenmayer, J P Hanke
1Department of Nuclear Medicine, Eberhard Karls University, Tuebingen, Germany.
Summary
Combining iodine-131 (131I) scintigraphy and fluorine-18-fluorodeoxyglucose (18FDG) PET whole-body scanning improves thyroid cancer metastasis detection. This dual-tracer approach enhances sensitivity, identifying tumors with varied metabolic and uptake characteristics.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- Differentiated thyroid carcinoma (DTC) management requires sensitive detection of metastases.
- Conventional imaging methods may not detect all thyroid cancer recurrences or metastases.
Purpose of the Study:
- To define the sensitivity of 131I scintigraphy and 18FDG PET whole-body scanning for detecting thyroid cancer and metastases.
- To evaluate the combined utility of these imaging modalities.
Main Methods:
- Prospective study of 41 differentiated thyroid carcinoma patients post-thyroidectomy and 131I ablation.
- Patients underwent 52 examinations using both 18FDG whole-body PET and 131I whole-body scanning.
Main Results:
- Combined 18FDG and 131I imaging achieved approximately 95% sensitivity.
- Alternating uptake patterns (131I-avid or 18FDG-avid metastases) were observed in about 90% of patients.
- 18FDG PET successfully localized histologically confirmed neck metastases in six patients with rising thyroglobulin levels.
Conclusions:
- A combined 18FDG and 131I whole-body imaging protocol effectively detects local recurrence and metastases, often missed by other methods.
- This combined approach may enable biochemical grading of thyroid cancer based on glucose metabolism and iodine uptake.
- 18FDG uptake appears to indicate poor functional differentiation and potentially higher malignancy in thyroid cancer.